Cost-Effectiveness of Biomarker-Associated Early Pancreatic Cancer Detection in New-Onset Diabetes
In this economic evaluation of early PDAC detection among individuals with new-onset diabetes, the application of a primary T3cD biomarker followed by a secondary PDAC-specific test was more cost-effective than the sole use of either biomarker, although no strategy was cost-effective compared with standard of care. These findings can be used to inform biomarker-associated early detection strategies for PDAC.
Authors
- Eithne Costello (ORCID: https://orcid.org/0000-0002-0104-8992)
- Nathan E. Thompson (ORCID: https://orcid.org/0000-0003-2302-1536)
- Daniel H. Palmer (ORCID: https://orcid.org/0000-0002-5766-9990)
- Lucy Oldfield (ORCID: https://orcid.org/0000-0002-0839-402X)
- Robert N. Hanson (ORCID: https://orcid.org/0000-0002-1159-6909)
- Robert Van Der Meer (ORCID: https://orcid.org/0000-0002-9442-1628)
- Christopher Halloran (ORCID: https://orcid.org/0000-0002-5471-4178)
- Irena Stefanova (ORCID: https://orcid.org/0000-0002-4024-0514)
- Martyn Stott (ORCID: https://orcid.org/0000-0002-3536-8281)
- William Greenhalf
Institutions
- University of Liverpool (GB)
- University of Strathclyde (GB)
- Royal Liverpool University Hospital (GB)
- Clatterbridge Cancer Centre NHS Foundation Trust (GB)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.38031
- Citations
- 2
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Pancreatic Cancer UK
- Cancer Research UK
- Liverpool University Hospitals NHS Foundation Trust